- NCIt
- C162566
Loading cancer entity…
Loading cancer entity…
Clinical trials
12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | recruiting | Phase 2 | 80 | Roswell Park Cancer InstituteOTHER | 1 | Aug 14, 2026 |
| clinicaltrials |
| NCT04919629 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | recruiting | Phase 2 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials